On the other hand, the abrupt cessation of JAK2 inhibitor (ruxolitinib) may result in progressive disease or rarely cytokine storm which worsens the clinical course of SARS-Cov-2 infection, and it has been suggested that ruxolitinib it can be a possible therapy for cytokines storm in critically ill COVID-19 patients (24). Here, JAK2 is linked to COVID-19.